'Bullish Options Flow' in Teva Pharma (TEVA) Continues -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to 'Bullish Options Flow' in Teva Pharma (TEVA) Continues -Susquehanna
November 30, 2017 12:22 PM EST
Cantor Fitzgerald analyst Louise Chen weighed in on the TASE index weight re-balancing for Mylan (NYSE: MYL) and Teva (NASDAQ: TEVA) after Mylan announced it is voluntarily delisting its ordinary shares from trading on the Tel Aviv Stock Exchange... More
November 29, 2017 5:07 PM EST
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data from the pivotal Phase III HALO study evaluating the efficacy, safety and tolerability of two subcutaneous dose regimens of fremanezumab for the preventive treatment of chronic migraine (CM). These data were published online today by the New England Journal of Medicine (NEJM) and will appear in a subsequent print issue.
The burden of illness faced by those with migraine is immense and can negatively impact every facet of their lives underscoring a significant unmet... More
November 29, 2017 2:45 PM EST
Susquehanna options strategist Alison Edwards notes continued buying activity Teva Pharma (NYSE: TEVA) , as an opening investor bought 15k Jan 15 Calls, most for $1.10, creating ~750k shares to buy.
...
More
November 29, 2017 6:45 AM EST
Mizuho Securities raised its price target on Teva Pharma (NYSE: TEVA) to $16.00 (from $12.00) while maintaining a Neutral rating, following a model update fueled by conversations with management.
Analyst Irina Koffler notes a positive outlook on the shares, following conversations with management... More
